A Study Of Tasocitinib In Dry Eye Subjects

Summary

This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease. Both subjective and objective clinical endpoints will be measured for a duration of 12-week treatment.

Timeline

Start

2010-12-01

Primary completion

2012-10-19

Completion

2012-10-19

Drugs

Indications